DiaMedica Therapeutics (DMAC)
(Real Time Quote from BATS)
$4.39 USD
+0.04 (0.92%)
Updated Sep 18, 2024 03:28 PM ET
2-Buy of 5 2
D Value F Growth C Momentum D VGM
Brokerage Reports
DiaMedica Therapeutics, Inc. [DMAC]
Reports for Purchase
Showing records 1 - 19 ( 19 total )
Company: DiaMedica Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: DiaMedica Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: DiaMedica Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: DiaMedica Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: DiaMedica Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: DiaMedica Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: DiaMedica Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: DiaMedica Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: DiaMedica Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: DiaMedica Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: DiaMedica Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: DiaMedica Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: DiaMedica Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: DiaMedica Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: DiaMedica Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: DiaMedica Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: DiaMedica Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: DiaMedica Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: DiaMedica Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare- Join our Call Today at 11AM to Unlock the Potential of DM199 in CKD and Stroke
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
|